Patent US5459058A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5459058A Expired / Lapsed US ⏱️ 0.0 years remaining

Cell culture system

Assignee: Individual
•
Filing: 1994-11-21
•
Granted: 1995-10-17
•
Expires: 2014-11-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Disclosed is a method for the culture of higher eukaryotic cells which are dependent for survival on an exogenous factor. The method involves co-culturing the factor-dependent cells with an immortalized eukaryotic cell that has been engineered to secrete the requisite factor. Also disclosed is a cell line of non-stromal cell origin which secretes interleukin-7.

Inventors

  • 👤 Philip Leder
  • 👤 Benjamin E. Rich

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 16:48
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/5418; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0634; C12N5/0635; C12N5/0636; A; A61; A61K; A61K35/00; A61K35/12; A61K2035/124; C12N2501/00; C12N2501/20; C12N2501/23; C12N2502/00; C12N2502/13; C12N2502/1394; C12N2502/99

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 35 words
A method for culturing a lymphoid cell which is dependent for survival upon an interleukin, said method comprising co-culturing said cell with an immortalized higher eukaryotic cell that has been engineered to secrete said interleukin.
Claim 2
Independent Claim 35 words
A method for culturing a lymphoid cell which is dependent for survival upon an interleukin, said method comprising co-culturing said cell with an immortalized higher eukaryotic cell that has been engineered to secrete said interleukin.
Claim 3
Dependent Claim 23 words
The method of claim 1, wherein said lymphoid cell dependent for survival upon an interleukin is further dependent for survival on cell-cell contact.
Claim 4
Dependent Claim 19 words
The method of claim 1, wherein said lymphoid cell dependent for survival upon an interleukin is a non-adherent cell.
Claim 5
Dependent Claim 19 words
The method of claim 1, wherein said lymphoid cell dependent for survival upon an interleukin is a human cell.
Claim 6
Dependent Claim 13 words
The method of claim 1, wherein said lymphoid cell is a B-lineage lymphocyte.
Claim 7
Dependent Claim 13 words
The method of claim 1, wherein said lymphoid cell is a T-lineage lymphocyte.
Claim 8
Dependent Claim 12 words
The method of claim 1, wherein said lymphoid cell is a thymocyte.
Claim 9
Dependent Claim 15 words
The method of claim 1, wherein said immortalized higher eukaryotic cell is an adherent cell.
Claim 10
Dependent Claim 15 words
The method of claim 1, wherein said immortalized higher eukaryotic cell is a mammalian cell.
Claim 11
Dependent Claim 13 words
The method of claim 9, wherein said mammalian cell is a human cell.
Claim 12
Dependent Claim 15 words
The method of claim 1, wherein said immortalized higher eukaryotic cell is a fibroblast cell.
Claim 13
Dependent Claim 13 words
The method of claim 11, wherein said fibroblast cell is an NIH3T3 cell.
Claim 14
Dependent Claim 10 words
The method of claim 1, wherein said interleukin is IL-7.
Claim 15
Dependent Claim 21 words
The method of claim 13, wherein said IL-7 is expressed from a stably transfected gene in said immortalized higher eukaryotic cell.
Claim 16
Dependent Claim 13 words
The method of claim 14, wherein said stably transfected gene comprises an enhancer.
Claim 17
Dependent Claim 13 words
The method of claim 15, wherein said IL-7 is encoded by plasmid pNAIL-7.
Claim 18
Dependent Claim 10 words
The method of claim 1, wherein said culturing is long-term.
Claim 19
Dependent Claim 35 words
The method of claim 1, further comprising contacting said immortalized higher eukaryotic cell with a growth-inhibitory amount of mitomycin-C just prior to co-culturing with said lymphoid cell which is dependent for survival upon an interleukin.

References Cited (Backward Citations)

US5030105A Cited
US4965195A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-10-16 1999-04-17 1999-10-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-10-16 2003-04-17 2003-10-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-10-16 2007-04-17 2007-10-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag